Detalhe da pesquisa
1.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795891
2.
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
N Engl J Med
; 388(17): 1547-1558, 2023 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912538
3.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 23(10): 1308-1320, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36113498
4.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
BJU Int
; 130(3): 370-380, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373443
5.
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Br J Cancer
; 123(7): 1063-1070, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669672
6.
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
BJU Int
; 125(4): 506-514, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900963
7.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol
; 20(11): 1531-1543, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31540791
8.
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
N Engl J Med
; 375(15): 1415-1424, 2016 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27626136
9.
Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Int J Clin Pract
; 73(9): 1-6, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30414348
10.
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting.
BJU Int
; 122(1): 13-25, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29699001
11.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
12.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
BJU Int
; 119(4): 522-529, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27256016
13.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 17(8): 1047-1060, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339115
14.
Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation.
J Immunol
; 192(7): 3101-10, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24600032
15.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 16(16): 1605-16, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26522334
16.
Abiraterone and increased survival in metastatic prostate cancer.
N Engl J Med
; 364(21): 1995-2005, 2011 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21612468
17.
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Lancet Oncol
; 14(7): 627-37, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23623280
18.
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Lancet Oncol
; 14(4): 317-26, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23474363
19.
Multi-institutional evaluation of a Pareto navigation guided automated radiotherapy planning solution for prostate cancer.
Radiat Oncol
; 19(1): 45, 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38589961
20.
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Cells
; 13(8)2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667288